Placental human papillomavirus infections and adverse pregnancy outcomes.

Genital HPV infection Human papillomavirus Placental biopsies Placental dysfunction syndromes PreventADALL

Journal

Placenta
ISSN: 1532-3102
Titre abrégé: Placenta
Pays: Netherlands
ID NLM: 8006349

Informations de publication

Date de publication:
11 May 2024
Historique:
received: 11 01 2024
revised: 29 04 2024
accepted: 07 05 2024
medline: 21 5 2024
pubmed: 21 5 2024
entrez: 20 5 2024
Statut: aheadofprint

Résumé

Knowledge on prevalence and association of human papillomavirus (HPV) in third trimester placentae and adverse pregnancy outcomes is limited. We investigated the prevalence of placental HPV at delivery, explored urine HPV characteristics associated with placental HPV and whether placental HPV increased the risk adverse pregnancy outcomes. Pregnant women were enrolled in the Scandinavian PreventADALL mother-child cohort study at midgestation. Human papillomavirus genotyping was performed on placental biopsies collected at delivery (n = 587) and first-void urine at midgestation and delivery (n = 556). Maternal characteristics were collected by questionnaires at gestational week 18 and 34. Adverse pregnancy outcomes were registered from chart data including hypertensive disorders of pregnancy, gestational diabetes mellitus and newborns small for gestational age. Uni- and multivariable regression models were used to investigate associations. Placental HPV was detected in 18/587 (3 %). Twenty-eight genotypes were identified among the 214/556 (38 %) with midgestational urine HPV. Seventeen of the 18 women with placental HPV were midgestational HPV positive with 89 % genotype concordance. Midgestational high-risk-(HR)-HPV and high viral loads of Any- or HR-HPV were associated with placental HPV. Persisting HPV infection from midgestation to delivery was not associated with placental HPV. Adverse pregnancy outcomes were seen in 2/556 (0.4 %) of women with placental HPV. In this general cohort of pregnant women, the prevalence of placental HPV was 3 %, and midgestational urinary HPV 38 %. High HPV viral load increased the risk for placental HPV infections. We observed no increased risk for adverse pregnancy outcomes in women with placental HPV.

Identifiants

pubmed: 38768555
pii: S0143-4004(24)00240-6
doi: 10.1016/j.placenta.2024.05.126
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-30

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Auteurs

Magdalena R Værnesbranden (MR)

Department of Obstetrics and Gynecology, Østfold Hospital Trust, Kalnes, Norway; University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway. Electronic address: c.m.r.varnesbranden@studmed.uio.no.

Anne Cathrine Staff (AC)

University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway; Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.

Johanna Wiik (J)

Department of Obstetrics and Gynecology, Østfold Hospital Trust, Kalnes, Norway; Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Katrine Sjøborg (K)

Department of Obstetrics and Gynecology, Østfold Hospital Trust, Kalnes, Norway.

Corina S Rueegg (CS)

Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.

Meryam Sugulle (M)

University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway; Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.

Karin C Lødrup Carlsen (KC)

University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway; Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Berit Granum (B)

Department of Chemical Toxicology, Norwegian Institute of Public Health, Oslo, Norway.

Guttorm Haugen (G)

University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway; Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.

Gunilla Hedlin (G)

Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Camilla G Johannessen (CG)

Genetic Unit, Centre for Laboratory Medicine, Østfold Hospital Trust, Kalnes, Norway.

Björn Nordlund (B)

Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Camilla F Nystrand (CF)

Genetic Unit, Centre for Laboratory Medicine, Østfold Hospital Trust, Kalnes, Norway.

Anbjørg Rangberg (A)

Genetic Unit, Centre for Laboratory Medicine, Østfold Hospital Trust, Kalnes, Norway.

Eva M Rehbinder (EM)

University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway; Department of Dermatology and Venereology, Oslo University Hospital, Oslo, Norway.

Knut Rudi (K)

Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.

Yvonne Sandberg (Y)

Genetic Unit, Centre for Laboratory Medicine, Østfold Hospital Trust, Kalnes, Norway.

Håvard O Skjerven (HO)

University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway; Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Cilla Söderhäll (C)

Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Riyas Vettukattil (R)

University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway; Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Christine M Jonassen (CM)

Genetic Unit, Centre for Laboratory Medicine, Østfold Hospital Trust, Kalnes, Norway; Department of Virology, Norwegian Institute of Public Health, Oslo, Norway.

Classifications MeSH